Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: July 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202992

« Back to Dashboard

NDA 202992 describes AUBAGIO, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the AUBAGIO profile page.

The generic ingredient in AUBAGIO is teriflunomide. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the teriflunomide profile page.

Summary for 202992

Tradename:	AUBAGIO
Applicant:	Sanofi Aventis Us
Ingredient:	teriflunomide
Patents:	3

Generic Entry Opportunity Date for 202992

Generic Entry Date for 202992^: ➤ Try a Free Trial* Constraining patent/regulatory exclusivity: ➤ Try a Free Trial Dosage:: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 202992

Mechanism of Action	Dihydroorotate Dehydrogenase Inhibitors

Suppliers and Packaging for NDA: 202992

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
AUBAGIO	teriflunomide	TABLET;ORAL	202992	NDA	Genzyme Corp.	58468-0210	N	58468-0210-1
AUBAGIO	teriflunomide	TABLET;ORAL	202992	NDA	Genzyme Corp.	58468-0210	N	58468-0210-2

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	7MG
Approval Date:	Sep 12, 2012	TE:		RLD:	Yes
Patent:	➤ Try a Free Trial	Patent Expiration:	Sep 12, 2026	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
Patent:	➤ Try a Free Trial	Patent Expiration:	Sep 14, 2030	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	➤ Try a Free Trial	Patent Expiration:	Feb 4, 2034	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE

Expired US Patents for NDA 202992

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-001	Sep 12, 2012	➤ Try a Free Trial	➤ Try a Free Trial
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-002	Sep 12, 2012	➤ Try a Free Trial	➤ Try a Free Trial
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-001	Sep 12, 2012	➤ Try a Free Trial	➤ Try a Free Trial
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-002	Sep 12, 2012	➤ Try a Free Trial	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.